Abstracts related event, adjusting for gender, age, ethnicity, presence of co-morbid respiratory diseases, number of other comorbidities, pre-index use of short-acting beta agonists (SABAs), oral steroids and theophylline, and pre-index events. RESULTS: A total of 4447 patients were identified, 2435 (55%) on IPR, 1088 (24%) on ICS alone, 410 (9%) on ICS + IPR, 299 (7%) on SAL alone and 215 (5%) on ICS + SAL. Compared to IPR alone, the use of ICS alone (HR 0.82, 95% CI: 0.69, 0.96), SAL alone (HR 0.62, 95% CI: 0.46, 0.84), and ICS + SAL (HR 0.64, 95% CI: 0.45, 0.91) were associated with a lower event risk when controlling for the other factors. Factors that were significant predictors of an increase risk of an event were: being white, having a co-morbid respiratory disease, using pre-index SABAs, and having pre-index events.
OBJECTIVES:
The purpose of this abstract is to examine the use of long-term asthma controller medications (LTACM) before and after asthma-related inpatient stays and emergency department events (EDE). METHODS: Data was drawn from the 1997 Medstat-Marketscan claims database. Asthma-related events were defined as EDE or inpatient hospital stay with a primary or secondary diagnosis of asthma (ICD-9 code 493). LTACM included corticosteroids, xanthines, leukotriene modifiers and combination medications. RESULTS: The sample included 464 individuals with an asthma-related EDE and 747 with an inpatient hospital stay. Of the EDE sample, 60% filled a prescription for LTACM during the calendar year. A total of 32% had filled a prescription prior to the EDE with an average of 85 days between the prescription being filled and the EDE. Twenty percent filled a prescription during the month subsequent to the EDE and 35% during the subsequent calendar year. Of those with a hospital stay, 60% filled a prescription for LTACM during the calendar year. Of those that filled a prescription prior to the hospitalization, there was an average of 70.4 days between the filling of the prescription and the event. Forty four percent of the hospital sample filled a prescription afterward, with 65% doing so within 30 days. CONCLUSIONS: We find that many of those receiving care in inpatient ad emergency departments are not using long-term controller medications. It is likely that virtually all of these individuals have been prescribed medications, but have not complied with the drug regimen. Even after an adverse event, a slight majority continues to not fill prescriptions. One approach for improving the health of those with asthma and reducing asthma expenditures. 
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COMPARISON OF THE ECONOMIC IMPACT OF MONTELUKAST AND INHALED CORTICOSTEROID AGENTS ON ALLERGIC RHINITIS-RELATED UTILIZATION IN PATIENTS
OBJECTIVES:
Montelukast has been approved for the treatment of seasonal allergic rhinitis. The study's objective was to compare allergic rhinitis (AR) associated medical and pharmacy utilization in asthma patients with comorbid AR initiating inhaled corticosteroids (ICS) or montelukast (MO). METHODS: A retrospective, observational study using healthcare claims from 25 United Healthcare plans was conducted. Subjects less than 65 years old and newly started on either ICS or MO between 01.01.1999 and 12.31.2000 were identified. Subjects with at least one asthma (493.xx) and one AR (477.xx) medical claim, 24 months of continuous enrollment, and either an AR claim or a non-sedating antihistamine (NSA) during the 12-month baseline were included. A logistic propensity score model was constructed utilizing AR, asthma and total health services utilization in the baseline period and matched cohorts selected based on a propensity score difference of £0.01. During the 12-month follow-up, the total number of NSA and nasal corticosteroid (NCS) refills, total days supply of NSA received, total AR pharmacy cost (not including asthma medications) and total AR health services cost (pharmacy + medical) were determined. Wilcoxon rank sum was used to test median differences in AR utilization. RESULTS: A total of 1706 subjects were matched, (853 ICS and 853 MO). Compared to ICS subjects, MO subjects received significantly more refills for NSA (median of 2.55 vs. 3.34, p < 0.0001), significantly more days of NSA therapy (median days supply of 30 vs. 60, p = 0.0001), and fewer NCS refills (median of 0.63 vs. 0.54, p = 0.0459). Additionally, MO subjects had significantly higher median AR pharmacy cost ($130 vs. $107, p = 0.0028) and total AR cost ($279 vs. $214, p = 0.0180). CONCLUSIONS: In this population, compared with ICS, the use of MO in asthma subjects with comorbid AR was associated with greater AR health services cost in the 12-month follow-up period.
